Evidence map›Paper›PMID 38743195›Full record

ReviewPhotochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology2024

Cyclic AMP-regulatory element-binding protein: a novel UV-targeted transcription factor in skin cancer.

Julianne C Nayar, Myriam Abboud, Katie M Dixon

Abstract readReview
PubMed Publisher
In one paragraph

Review in Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Multi-faceted regulation of CREB family transcription factors.Frontiers in molecular neuroscience · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Julianne C NayarSchool of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, 2050, Camperdown, NSW, Australia.ORCID http://orcid.org/0009-0007-9427-4502
Myriam AbboudDepartment of Health, Zayed University, P.O. Box 144534, Abu Dhabi, United Arab Emirates.ORCID http://orcid.org/0000-0001-8025-7823
Katie M DixonSchool of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, 2050, Camperdown, NSW, Australia. katie.dixon@sydney.edu.au.ORCID http://orcid.org/0000-0002-3516-3083

Funding

Zayed University Research Office Provost Award Grant R21055
6 · The paper itself

Abstract

Common therapeutics in relation to melanoma and non-melanoma cancers include the use of kinase inhibitors. The long-term benefits of kinases, however, are limited by development of drug resistance. An alternative approach for treatment would be to focus on transcription factors. Cyclic AMP-regulatory element-binding protein (CREB) is a transcription factor that is commonly overactivated or overexpressed in many different cancers including skin cancer. Ultraviolet radiation (UVR), one of the main causes of skin cancer, can activate CREB in both melanocytes and keratinocytes. In addition, CREB has been found to be activated in skin cancers. Considering the prominent role that CREB plays in skin cancers, the studies reviewed herein raise the possibility of CREB as a potential prognostic and diagnostic marker of skin cancer and a novel target for therapeutic intervention.

Indexed as

Cyclic AMP Response Element-Binding ProteinSkin NeoplasmsUltraviolet RaysAnimalsHumansCyclic AMP Response Element-Binding ProteincAMP-regulatory element-binding protein (CREB)Melanoma skin cancerNon-melanoma skin cancerUltraviolet radiation

Identifiers

PMID38743195

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.